Skip to main content
. 2017 Oct 26;9(1):152–166. doi: 10.18632/oncotarget.22077

Figure 6. In vivo antitumor efficacy of deguelin in human hepatocellular PDX tumor models.

Figure 6

(A–C) Deguelin significantly inhibits tumor growth in a PDX tumor model compared to a vehicle-treated group. B-17 SCID mice each implanted with a different patient’s tumor were divided into 2 groups. Mice implanted with Case 1 (left, n = 10), Case 2 (middle, n = 10) or Case 3 (right, n = 10) were treated every three days by i.p. injection with vehicle or deguelin. (A) Tumor growth curve. (B) Photograph of tumors in the vehicle and deguelin-treated group. (C) Average tumor weight. (D) The change of body weight of tumor-bearing mice during the experiment. Data are represented as mean values ± S.D. The asterisks indicate significant differences (*p < 0.05, **p < 0.01, **p < 0.001) between deguelin-treated and vehicle-treated group.